Feature | Cardiac Amyloidosis and How to Stop Missing the Diagnosis – American College of Cardiology
Cardiac amyloidosis used to be considered an ultra-rare disease with no treatment options. No longer. Advances in noninvasive testing have led to greater awareness, earlier diagnosis and improved outcomes for patients. Concurrently, important advancements in the treatment of ATTR amyloidosis have significantly changed the landscape of care for those affected by the disease. But these important gains come with a caveat. The disease is underdiagnosed. If clinicians don’t detect and diagnose the disease